让跨性别群体的生育能力得以保留。

IF 4.1 2区医学 Q1 OBSTETRICS & GYNECOLOGY

Best Practice & Research Clinical Obstetrics & Gynaecology Pub Date : 2025-07-24 DOI:10.1016/j.bpobgyn.2025.102652

Suset Rodriguez, Pasquale Patrizio

{"title":"让跨性别群体的生育能力得以保留。","authors":"Suset Rodriguez, Pasquale Patrizio","doi":"10.1016/j.bpobgyn.2025.102652","DOIUrl":null,"url":null,"abstract":"<div><div>Transgender individuals, whose gender identity differs from their assigned sex at birth, may undergo gender-affirming hormone therapy (GAHT) and gender-affirming surgery (GAS) to alleviate gender dysphoria. These treatments often impact future reproductive potential, necessitating fertility preservation (FP) discussions. Healthcare guidelines from the American Society of Reproductive Medicine (ASRM), World Professional Association for Transgender Health (WPATH), and the Endocrine Society recommend counseling on FP options, which include oocyte, sperm, and embryo cryopreservation. Challenges remain, including the impact of gender dysphoria during FP processes, the recommended length of being off hormonal treatments, the financial burden, and limited data on future pregnancy outcomes. This chapter explores FP options for transgender individuals, including those with ovaries or testes, and addresses challenges to utilization.</div></div>","PeriodicalId":50732,"journal":{"name":"Best Practice & Research Clinical Obstetrics & Gynaecology","volume":"102 ","pages":"Article 102652"},"PeriodicalIF":4.1000,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Making fertility preservation happen for the transgender community\",\"authors\":\"Suset Rodriguez, Pasquale Patrizio\",\"doi\":\"10.1016/j.bpobgyn.2025.102652\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Transgender individuals, whose gender identity differs from their assigned sex at birth, may undergo gender-affirming hormone therapy (GAHT) and gender-affirming surgery (GAS) to alleviate gender dysphoria. These treatments often impact future reproductive potential, necessitating fertility preservation (FP) discussions. Healthcare guidelines from the American Society of Reproductive Medicine (ASRM), World Professional Association for Transgender Health (WPATH), and the Endocrine Society recommend counseling on FP options, which include oocyte, sperm, and embryo cryopreservation. Challenges remain, including the impact of gender dysphoria during FP processes, the recommended length of being off hormonal treatments, the financial burden, and limited data on future pregnancy outcomes. This chapter explores FP options for transgender individuals, including those with ovaries or testes, and addresses challenges to utilization.</div></div>\",\"PeriodicalId\":50732,\"journal\":{\"name\":\"Best Practice & Research Clinical Obstetrics & Gynaecology\",\"volume\":\"102 \",\"pages\":\"Article 102652\"},\"PeriodicalIF\":4.1000,\"publicationDate\":\"2025-07-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Best Practice & Research Clinical Obstetrics & Gynaecology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1521693425000768\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Best Practice & Research Clinical Obstetrics & Gynaecology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1521693425000768","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

性别认同与其出生时的生理性别不同的跨性别者，可能会接受性别确认激素治疗（GAHT）和性别确认手术（GAS）来缓解性别焦虑。这些治疗往往影响未来的生殖潜力，需要生育保护（FP）的讨论。美国生殖医学会（ASRM）、世界跨性别健康专业协会（WPATH）和内分泌学会的医疗保健指南建议对计划生育方案进行咨询，包括卵母细胞、精子和胚胎冷冻保存。挑战依然存在，包括计划生育过程中性别焦虑的影响、停止激素治疗的推荐时间、经济负担以及关于未来妊娠结局的有限数据。本章探讨了跨性别者（包括那些有卵巢或睾丸的人）的计划生育选择，并解决了利用计划生育的挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Making fertility preservation happen for the transgender community

Transgender individuals, whose gender identity differs from their assigned sex at birth, may undergo gender-affirming hormone therapy (GAHT) and gender-affirming surgery (GAS) to alleviate gender dysphoria. These treatments often impact future reproductive potential, necessitating fertility preservation (FP) discussions. Healthcare guidelines from the American Society of Reproductive Medicine (ASRM), World Professional Association for Transgender Health (WPATH), and the Endocrine Society recommend counseling on FP options, which include oocyte, sperm, and embryo cryopreservation. Challenges remain, including the impact of gender dysphoria during FP processes, the recommended length of being off hormonal treatments, the financial burden, and limited data on future pregnancy outcomes. This chapter explores FP options for transgender individuals, including those with ovaries or testes, and addresses challenges to utilization.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Best Practice & Research Clinical Obstetrics & Gynaecology 医学-妇产科学

CiteScore

9.40

自引率

1.80%

发文量

113

审稿时长

54 days

期刊介绍： In practical paperback format, each 200 page topic-based issue of Best Practice & Research Clinical Obstetrics & Gynaecology will provide a comprehensive review of current clinical practice and thinking within the specialties of obstetrics and gynaecology. All chapters take the form of practical, evidence-based reviews that seek to address key clinical issues of diagnosis, treatment and patient management. Each issue follows a problem-orientated approach that focuses on the key questions to be addressed, clearly defining what is known and not known. Management will be described in practical terms so that it can be applied to the individual patient.